Cargando…

MARC

LEADER 00000cam a2200000 i 4500
001 EBSCO_ocn761307745
003 OCoLC
005 20231017213018.0
006 m o d
007 cr |||||||||||
008 100827s2011 nyua ob 001 0 eng
010 |a  2020678359 
040 |a DLC  |b eng  |e rda  |e pn  |c DLC  |d YDXCP  |d E7B  |d OCLCF  |d NLGGC  |d EBLCP  |d DEBSZ  |d AZK  |d MERUC  |d AGLDB  |d MOR  |d PIFAG  |d ZCU  |d U3W  |d STF  |d WRM  |d VTS  |d NRAMU  |d ICG  |d VT2  |d AU@  |d WYU  |d A6Q  |d DKC  |d UKCRE  |d BOL  |d N$T  |d OCLCO  |d VLY  |d AJS  |d OCLCO  |d OCLCQ  |d OCLCO 
019 |a 961534321  |a 962711624  |a 988523497  |a 992002951  |a 1037944403  |a 1038689371  |a 1045491739  |a 1055378407  |a 1058175500  |a 1066407900  |a 1081199291  |a 1083559348  |a 1114474655  |a 1119550660  |a 1153524977  |a 1162422950  |a 1259275787 
020 |a 9781611223606  |q (ebook) 
020 |a 1611223601 
020 |z 9781611220711  |q (hbk.) 
020 |z 1611220718 
029 1 |a AU@  |b 000051366736 
029 1 |a AU@  |b 000066119495 
029 1 |a DEBBG  |b BV043098871 
029 1 |a DEBBG  |b BV044087764 
029 1 |a DEBSZ  |b 421511230 
029 1 |a DEBSZ  |b 449538915 
029 1 |a NZ1  |b 15025310 
035 |a (OCoLC)761307745  |z (OCoLC)961534321  |z (OCoLC)962711624  |z (OCoLC)988523497  |z (OCoLC)992002951  |z (OCoLC)1037944403  |z (OCoLC)1038689371  |z (OCoLC)1045491739  |z (OCoLC)1055378407  |z (OCoLC)1058175500  |z (OCoLC)1066407900  |z (OCoLC)1081199291  |z (OCoLC)1083559348  |z (OCoLC)1114474655  |z (OCoLC)1119550660  |z (OCoLC)1153524977  |z (OCoLC)1162422950  |z (OCoLC)1259275787 
043 |a n-us--- 
050 0 0 |a HD9666.4 
072 7 |a BUS  |x 070000  |2 bisacsh 
082 0 0 |a 338.4/361510973  |2 22 
049 |a UAMI 
245 0 0 |a Generic drugs :  |b the pay-for-delay problem /  |c Christina M. Curtin, editor. 
264 1 |a New York :  |b Nova Biomedical/Nova Science Publishers,  |c [2011] 
300 |a 1 online resource 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
340 |g polychrome.  |2 rdacc  |0 http://rdaregistry.info/termList/RDAColourContent/1003 
347 |a data file 
490 1 |a Public health in the 21st century 
504 |a Includes bibliographical references and index. 
588 0 |a Print version record and CIP data provided by publisher. 
505 0 |a GENERIC DRUGS: THE PAY-FOR-DELAY PROBLEM ; GENERIC DRUGS: THE PAY-FOR- DELAY PROBLEM; CONTENTS; PREFACE; PAY-FOR-DELAY: HOW DRUG COMPANY PAY-OFFS COST CONSUMERS BILLIONS; SUMMARY ; RECOMMENDATION; BACKGROUND ; FINDINGS FROM PHARMACEUTICAL AGREEMENT FILINGS FROM FY2004 THROUGH FY2009; STUDY METHODOLOGY ; How Staff Calculated the Additional Delay in Generic Entry Associated with Agreements that Involved Compensation from the Brand to the Generic ; How Staff Calculated the Estimate of 3.5 Billion Annually that Consumers Lose due to Pay-For-Delay Agreements. 
505 8 |a (1) Consumer savings from generic competition (2) Likelihood of Settlements with Payment to Delay, and the Length of Delay; (3) Sales Volume of Drugs for which Settlements are Likely ; (4) Final Estimate Calculation ; Results with Varied Assumptions ; End Notes ; "PAY-FOR-DELAY" SETTLEMENTS IN THE PHARMACEUTICAL INDUSTRY: HOW CONGRESS CAN STOP ANTICOMPETITIVE CONDUCT, PROTECT CONSUMERS' WALLETS, AND HELP PAY FOR HEALTH CARE REFORM (THE 35 BILLION SOLUTION) ; A BRIEF HISTORY ; NEW FTC ANALYSIS OF EMPIRICAL DATA ; Savings to Consumers and the Federal Government ; ENCOURAGING SIGNS. 
505 8 |a LOOKING FORWARDAPPENDIX: CALCULATION OF CONSUMER SAVINGS ; Consumer Savings from Generic Competition ; Likelihood of Settlements with Payment to Delay, and the Length of Delay ; Sales Volume of Drugs for which Settlements are Likely ; Final Estimate Calculation ; Results with Varied Assumptions ; End Notes ; STATEMENT OF THE FEDERAL TRADE COMMISSION, BEFORE THE SUBCOMMITTEE ON COURTS AND COMPETITION POLICY, HEARING ON "ANTICOMPETITIVE PAY-FOR-DELAY SETTLEMENTS IN THE PHARMACEUTICAL INDUSTRY: WHY CONSUMERS AND THE FEDERAL GOVERNMENT ARE PAYING TOO MUCH FOR PRESCRIPTION DRUGS." 
505 8 |a I. THE NEED FOR A LEGISLATIVE SOLUTION A. Permissive Court Decisions have Made Pay-for-Delay Settlements Commonplace in Hatch-Waxman Patent Cases ; B. The Profitability of Delaying Generic Entry Means that these Agreements will become More Prevalent ; C. Pay-For-Delay Settlements Impose Enormous Costs on Consumers and the Health Care System ; D. Permissive Legal Treatment of Pay-for-Delay Settlements Undermines the Hatch-Waxman Act ; E. Legislation is Likely to be Swifter and More Comprehensive than Litigation. 
505 8 |a II. THE ARGUMENTS AGAINST BARRING EXCLUSION PAYMENTS ARE CONTRADICTED BY EXPERIENCE IN THE MARKET III. THE LEGISLATIVE REMEDY; CONCLUSION ; End Notes ; TESTIMONY OF HEATHER BRESCH, CHIEF OPERATING OFFICER, MYLAN, INC., BEFORE THE SUBCOMMITTEE ON COURTS AND COMPETITION POLICY, HEARING ON "PAY TO DELAY: ARE PATENT SETTLEMENTS THAT DELAY GENERIC DRUG MARKET ENTRY ANTICOMPETITIVE" ; A BRIEF HISTORY OF HATCH-WAXMAN ; AUTHORIZED GENERICS ; PATENT SETTLEMENTS. 
546 |a English. 
590 |a eBooks on EBSCOhost  |b EBSCO eBook Subscription Academic Collection - Worldwide 
650 0 |a Generic drugs  |x Prices. 
650 0 |a Drugs  |x Prices. 
650 0 |a Pharmaceutical industry  |z United States. 
650 6 |a Médicaments génériques  |x Prix. 
650 6 |a Médicaments  |x Prix. 
650 6 |a Industrie pharmaceutique  |z États-Unis. 
650 7 |a BUSINESS & ECONOMICS  |x Industries  |x General.  |2 bisacsh 
650 7 |a Drugs  |x Prices  |2 fast 
650 7 |a Generic drugs  |x Prices  |2 fast 
650 7 |a Pharmaceutical industry  |2 fast 
651 7 |a United States  |2 fast 
700 1 |a Curtin, Christina M. 
776 0 8 |i Print version:  |t Generic drugs.  |d New York : Nova Biomedical/Nova Science Publishers, ©2011  |z 9781611220711  |w (DLC) 2010036382 
830 0 |a Public health in the 21st century series. 
856 4 0 |u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=399726  |z Texto completo 
938 |a ProQuest Ebook Central  |b EBLB  |n EBL3018688 
938 |a ebrary  |b EBRY  |n ebr10661626 
938 |a EBSCOhost  |b EBSC  |n 399726 
938 |a YBP Library Services  |b YANK  |n 7267528 
994 |a 92  |b IZTAP